A composite approach that includes dropout rates when analyzing efficacy data in clinical trials of antipsychotic medications

Schizophrenia Bulletin

Volumn 34, Issue 6, 2008, Pages 1145-1150

  Rabinowitz, Jonathan ^a   Davidov, Ori ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

Author keywords

Clinical trials; Composite approach; Last observation carried forward; Missing data

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SERTINDOLE;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CHI SQUARE TEST; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; META ANALYSIS; PATIENT PARTICIPATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); DATA COLLECTION; HUMANS; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 54249163551     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm107     Document Type: Article

References (31)

1. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl). 2001;155:230-233.
2. Martin JL, Perez V, Sacristan M, Rodriguez-Artalejo F, Martinez C, Alvarez E. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry. 2006;21:11-20.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
4. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York, NY: John Wiley; 1987.
5. Mallinckrodt CH, Sanger TM, Dube S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003;53:754-760.
6. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396-1404.
7. Duan N, Kraemer HC, Mintz J. Antipsychotic drugs and schizophrenia. N Engl J Med. 2006;354: author reply 298-300.
8. Shih WJ, Quan H. Testing for treatment differences with dropouts present in clinical trials-a composite approach. Stat Med. 1997;16:1225-1239.
9. Shih WJ, Quan H. On the composite approach to dropouts in clinical trials. Stat Sin. 2001;11:53-61.
10. Fisher RA. Statistical Methods for Research Workers. 4th ed. Edinburgh, UK: Oliver and Boyd; 1932.
11. Edgington E. An additive method for combining probability values from independent experiments. J Psychol. 1972;80:351-363.
12. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York, NY: McGraw-Hill; 1971.
13. Mosteller F, Bush R. Selected quantitative techniques. In: Lindzey G, ed. Handbook of Social Psychology. Vol 1. Cambridge, Mass: Addison-Wesley; 1954. 289-334.
14. Tippett LHC. The Methods of Statistics; an Introduction Mainly for Workers in the Biological Sciences. 2nd ed. London, UK: Williams & Norgate Ltd; 1931.
15. Sutton AJ. Methods for meta-analysis in Medical Research. Chichester, NY: J. Wiley; 2000.
16. Rosenthal R. Meta-analytic Procedures for Social Research. Revised ed. Newbury Park, Calif: Sage Publications; 1991.
17. Keks NA, Ingham M, Akbara K, Keith K. Non-inferiority efficacy trial of risperidone long-acting injection (RLAI) vs. olanzapine tablets (OLA). Thirteenth Biennial Winter Workshop on Schizophrenia; February 4-10, 2006; Davos, Switzerland.
18. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999;45:403-411.
19. Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res. 2005;72:249-258.
20. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125-1132.
21. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry. 1999;156:610-616.
22. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
23. Wetzel H, Grunder G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. Amisulpride Study Group. Psychopharmacology (Berl). 1998;137:223-232.
24. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
25. Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol. 1998;13 (suppl 3):S65-S70.
26. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49:52-63.
27. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155:914-920.
28. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-774.
29. McMahon RP, Harrell FE Jr. Joint testing of mortality and a non-fatal outcome in clinical trials. Stat Med. 2001;20:1165-1172.
30. Rabinowitz J. Pattern Mixture Approach to Comparing Outcomes of Benefit in Guideline Development. Amsterdam, The Netherlands: ECNP; 2005.
31. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.